These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 34426442)

  • 21. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
    Siena S; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Fakih M; Elez E; Rodriguez J; Ciardiello F; Komatsu Y; Esaki T; Chung K; Wainberg Z; Sartore-Bianchi A; Saxena K; Yamamoto E; Bako E; Okuda Y; Shahidi J; Grothey A; Yoshino T;
    Lancet Oncol; 2021 Jun; 22(6):779-789. PubMed ID: 33961795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.
    Isogai A; Nozawa K; Nakakami A; Komaki R; Ozaki Y; Endo Y; Kataoka A; Kotani H; Yoshimura A; Hattori M; Sawaki M; Iwata H
    Breast Cancer Res Treat; 2024 Sep; 207(2):253-261. PubMed ID: 38797792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
    Mishima S; Shitara K
    Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
    [No Abstract]   [Full Text] [Related]  

  • 24. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
    Aoki M; Iwasa S; Boku N
    Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
    Li BT; Meric-Bernstam F; Bardia A; Naito Y; Siena S; Aftimos P; Anderson I; Curigliano G; de Miguel M; Kalra M; Oh DY; Park JO; Postel-Vinay S; Rha SY; Satoh T; Spanggaard I; Michelini F; Smith A; Machado KK; Saura C;
    Lancet Oncol; 2024 Jun; 25(6):707-719. PubMed ID: 38710187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.
    Yoshino T; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Wainberg Z; Elez E; Rodriguez J; Fakih M; Ciardiello F; Saxena K; Kobayashi K; Bako E; Okuda Y; Meinhardt G; Grothey A; Siena S;
    Nat Commun; 2023 Jun; 14(1):3332. PubMed ID: 37286557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
    Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
    Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
    Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
    Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate.
    Edoardo C; Giuseppe C
    Expert Opin Investig Drugs; 2024 Aug; 33(8):851-865. PubMed ID: 38967422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.
    Ciruelos E; García-Sáenz JÁ; Gavilá J; Martín M; Rodríguez CA; Rodríguez-Lescure Á
    Clin Transl Oncol; 2024 Jul; 26(7):1539-1548. PubMed ID: 38336982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
    N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
    Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Lee J; Saito K; Kawaguchi Y; Kamio T; Kojima A; Sugihara M; Yamaguchi K;
    N Engl J Med; 2020 Jun; 382(25):2419-2430. PubMed ID: 32469182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
    Meric-Bernstam F; Makker V; Oaknin A; Oh DY; Banerjee S; González-Martín A; Jung KH; Ługowska I; Manso L; Manzano A; Melichar B; Siena S; Stroyakovskiy D; Fielding A; Ma Y; Puvvada S; Shire N; Lee JY
    J Clin Oncol; 2024 Jan; 42(1):47-58. PubMed ID: 37870536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
    Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
    Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
    Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
    Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression.
    Rogawski D; Cao T; Ma Q; Roy-O'Reilly M; Yao L; Xu N; Nagpal S
    J Neurooncol; 2024 Oct; 170(1):209-217. PubMed ID: 39073687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab Deruxtecan in
    Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
    N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
    Nakajima H; Harano K; Nakai T; Kusuhara S; Nakao T; Funasaka C; Kondoh C; Matsubara N; Naito Y; Hosono A; Mitsunaga S; Ishii G; Mukohara T
    Breast; 2022 Feb; 61():136-144. PubMed ID: 34999427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.
    Mosele F; Deluche E; Lusque A; Le Bescond L; Filleron T; Pradat Y; Ducoulombier A; Pistilli B; Bachelot T; Viret F; Levy C; Signolle N; Alfaro A; Tran DTN; Garberis IJ; Talbot H; Christodoulidis S; Vakalopoulou M; Droin N; Stourm A; Kobayashi M; Kakegawa T; Lacroix L; Saulnier P; Job B; Deloger M; Jimenez M; Mahier C; Baris V; Laplante P; Kannouche P; Marty V; Lacroix-Triki M; Diéras V; André F
    Nat Med; 2023 Aug; 29(8):2110-2120. PubMed ID: 37488289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
    Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.